Ophthalmology Management

01/13/2026

🎉 Celebrating 30 years of Ophthalmology Management

This year marks 30 years of supporting ophthalmologists at the intersection of clinical care, surgical innovation, and practice.

Thank you to our editorial teams, contributors, and readers for being part of this journey.
🔗 https://ow.ly/qFBR50XWapW

01/09/2026

Post-op outcomes start before surgery. 👁️

In this article, Vance Thompson, MD explains why optimizing the ocular surface before and after surgery is key to reducing Surgical Temporary Ocular Discomfort Syndrome (STODS) and improving visual quality and patient satisfaction.

STODS is common, usually temporary, and often overlooked. Proactive screening, treatment, and surgical technique can make a real difference.

🔗 Read more: https://ow.ly/QYJq50XN57g

STODS can negatively impact patient satisfaction and surgical outcomes. Surgeons can reduce patient burden by identifying at-risk patients; optimizing the ocular surface before surgery; adopting surgical techniques that minimize disruption to the ocular surface; and managing postoperative symptoms p...

01/08/2026

Marketing budgets may be tight, but expectations for results have never been higher.

In this article, Amanda Robben, COE, shares practical, real-world strategies for ophthalmology practices to make every marketing dollar count, from smarter media choices and intentional social content to patient retention and low-cost in-office events.

🔗 Read the article: https://ow.ly/jVhc50XN534

Whether it’s shifting your media strategy, improving follow-up systems, or hosting community focused events, thriving on a limited marketing budget is possible.

01/06/2026

New global guidance on myopia is reshaping how we approach care. 🌍👁️

The International Myopia Institute 2025 Digest brings expert consensus on myopia definitions, risk factors, prevention, and management with a strong focus on early identification, personalized treatment, and lifestyle interventions.

Key takeaways for eye care professionals:
👁‍🗨 Pre-myopia matters. Hyperopic reserve is a critical predictor of future myopia
👁‍🗨 Delay equals protection. Each year onset is delayed can prevent years of progression
👁‍🗨 Outdoor time works. It remains the strongest protective factor
👁‍🗨 Personalized care wins. Optical interventions and risk-based strategies are supported by long-term evidence

As myopia rates rise worldwide, this guidance reinforces the importance of proactive, patient-centered care starting early. Read more in Ophthalmology Management: https://ow.ly/JlkB50XRQeJ

01/05/2026

✨ Starting 2025 with a reminder that cataract surgery is no longer one-size-fits-all.

From enhanced monofocals to EDOF and multifocal IOLs, today’s lens options allow us to tailor outcomes to how patients actually live, work, and see the world.

In Ophthalmology Management, Dagny Zhu, MD, with coauthors Ariana Rose Maleki, Jacklyn Vainshtein, and Irene Zhou, break down how understanding a patient’s lifestyle, visual priorities, and ocular health is key to choosing the right IOL - and setting the stage for better satisfaction.

👉 Read “A Lens for Every Lifestyle” to explore how thoughtful preop evaluation and patient education guide modern IOL selection:
🔗 https://ow.ly/nuZA50XM9Os

01/02/2026

Private equity or private practice? Many ophthalmologists are weighing the trade-offs.

This article explores both sides, from autonomy and patient relationships to scale, support, and work-life balance, with insights from ophthalmologists working in each model.

There’s no one-size-fits-all answer, just different priorities at different career stages.

🔗 Read more: https://ow.ly/vlZN50XN4Zc

12/30/2025

👁️ Here's everything you've missed in the news!

From clinical trial milestones and FDA updates to innovations in AI, retina, and cataract care, the Ophthalmology Management News hub rounds up the stories that mattered most in 2025.

Start 2026 informed. Stay ahead. 📰✨
👉 https://ow.ly/xgFW50XM9XE

12/26/2025

Okyo Pharma shared early Phase 2 trial results for urcosimod for chronic eye pain linked to damaged corneal nerves.

In a small study, people on 0.05% urcosimod reported less pain and their corneal images showed signs the nerves were healthier, compared with placebo. The company says this supports further research into urcosimod as a potential new treatment.

Read more: https://ow.ly/FzP150XN4Oe

12/23/2025

🚨 PATCH AMD milestone! 👁️‍🗨️

Regenerative Patch Technologies has treated the first 2 patients in a phase 2b trial testing an allogeneic bioengineered RPE implant for dry AMD with GA.

More details 👉 🔗 https://ow.ly/joV450XM9gl

12/22/2025

👁️ Presbyopia drops are revolutionizing care for aging eyes.

More than just a quick fix, they act as a strategic entry point for lifelong eye health.

Dr. Mitchell A. Jackson and Dr. Melissa Bollinger dive into how presbyopia drops offer flexibility, discretion, and customization - helping patients with age-related vision changes and laying the foundation for future treatments. 🌱

Read more on how these drops can transform your patients’ care in Ophthalmology Management 🔗 https://ow.ly/74aW50XKaBp

Presbyopia drops are more than just a new tool—they’re a strategic entry point into the lifelong care pathway for patients with presbyopia.

12/19/2025

👁️‍🗨️ Corneal scarring can steal vision - but transplant isn’t always the answer.

In this article, Sumitra S. Khandelwal, MD walks through a stepwise approach to medical + surgical management - from first-line medical therapy and scleral lenses to depth-based surgical options (superficial keratectomy, PTK, ALK/DALK), with PKP reserved for severe cases. 🩺

Read: Medical and Surgical Management of Corneal Scarring ⬇️
🔗 https://ow.ly/fYlh50XJIFw

12/18/2025

👁️ Laser “top-up” may help keep glaucoma pressure down 👇

A new independent, real-world study reported that MicroPulse transscleral laser retreatment can safely and effectively further lower eye pressure in people with moderate to advanced glaucoma.

At 3 months after retreatment, patients saw meaningful pressure reductions (~25–35%), including those who didn’t respond strongly to the first procedure.

👉 Read more: https://ow.ly/mv4H50XKpOM